Lukas Roell
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (33)
Year:
2026
Year:
2026
According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms, particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and may contribute to P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P3b subcomponent amplitudes and latencies, cognition, and symptom severity in SSD. In total, 107 patients and 107 healthy controls (HC) were included in the study, with the exact numbers varying across specific analyses. We grouped patients into higher (SSD+, N = 41) and lower (SSD−, N = 65) symptom severity clusters based on PANSS total scores. P3b amplitudes were lower in SSD patients than HC at central and parietal sites. SSD+ exhibited widespread P3b amplitude reductions, significant at parietal and trend-level at central and frontal regions, while SSD− showed a trend-level amplitude reduction limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P3b amplitudes at central and parietal sites within SSD− and overall SSD group. Although P3b amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P3b associations. Our findings suggest P3b amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher illness severity, and that enhanced lDLPFC GABA may contribute to offsetting these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns associated with cognitive dysfunction in SSD.
Year:
2026
Year:
2026
Year:
2026
When the brain and body misalign, emotional experience and sense of reality can be disrupted. Although such atypical experiences are central to schizophrenia spectrum disorders (SSD), interoception, processing of internal bodily signals, remains poorly understood in individuals with SSD, particularly across subjective, behavioural, and neural domains. We tested whether SSD is associated with convergent alterations across interoceptive domains and whether these relate to clinical symptoms in a cross-sectional observational design. Patients with SSD ( n = 53) and matched healthy controls (HC; n = 60) completed an EEG experiment comprising eyes-closed and eyes-open resting-state recordings and a heartbeat counting task (HCT), followed by self-report measures. Interoceptive accuracy was derived from the HCT, while cortical responses to afferent cardiac signals were indexed by heartbeat evoked potentials (HEP). In individuals with SSD, subjective interoceptive awareness was altered, characterised by impaired regulation and negative bodily appraisal, alongside elevated depersonalization. At the behavioral level, interoceptive accuracy was marginally lower. HEP positivity was attenuated, most clearly during HCT and, to a lesser extent, in eyes-open rest, over centro-parietal regions, consistent with context-dependent alterations in cortical processing of afferent bodily signals. Symptom–interoception links were largely modest, with depersonalization emerging as the most consistent correlate of clinical severity, suggesting that interoceptive disturbances in SSD may reflect a trait-like, disorder-central alteration. Together, these findings indicate that SSD involves pervasive disturbances in bodily self-experience, marked by impaired interoceptive regulation and by context-dependent neural attenuation during interoceptive engagement. This profile highlights interoceptive dysfunction as a disorder-central feature with potential prognostic and therapeutic relevance.
Year:
2026
Schizophrenia spectrum disorders (SSDs) are clinically and biologically heterogeneous and lack reliable biomarkers for stratification and outcome prediction. Evidence from postmortem, fluid biomarker, and neuroimaging studies suggests that blood–brain barrier (BBB) dysfunction may contribute to pathophysiology in a biologically defined subgroup. However, findings are inconsistent and often based on cross-sectional or indirect measures. The IMPACT study is a longitudinal, multimodal investigation designed to quantify BBB permeability across disease phases using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to integrate these measures with deep clinical phenotyping. We recruit inpatients with SSDs and healthy controls (HC). Participants undergo multimodal MRI including DCE-MRI at three time points: acute psychosis (baseline; V1), early treatment (4-6 weeks; V2), and long-term follow-up (2.5 years; V3). Clinical characterization includes standardized measures of psychopathology, functioning and cognition. Blood samples are collected at each visit, while CSF is obtained only when clinically indicated in the SSD group. DCE-MRI-derived voxelwise permeability metrics are then analyzed. Primary objectives are to (i) compare BBB leakage cross-sectionally between SSD and HC and (ii) characterize spatial and temporal leakage profiles across illness phases. Secondary objectives include analyzing associations with psychopathology and biological (e.g., inflammatory) signatures, as well as exploratory identification of subgroups. By providing a longitudinal, BBB-specific neuroimaging framework embedded in a deep phenotyping infrastructure, IMPACT aims to elucidate BBB alterations in SSDs and to support biologically informed stratification approaches in precision psychiatry.
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (32)
Enrico Schulz
Principle Investigator
Ludwig-Maximilians-Universität München
Daniel Keeser
RG Neuromodulation And Multimodal Neuroimaging, RG Clinical Deep Phenotyping (CDP)
Ludwig-Maximilians-Universität München
Andrea Schmitt
Klinikum der Universität München
Eva C. Schulte
Professor of Psychiatric Genomics, Division Head
Technical University of Munich
Brenda WJH Penninx
Professor
-
Zhuanghua Shi
Professor
Ludwig-Maximilians-Universität München
Sergi Papiol
University Hospital, LMU Munich
Astrid Roeh
University Hospital Augsburg
Florian Raabe
Group Leader & Deputy Chief Physician
Max Planck Institute of Psychiatry
Joseph Firth
The University of Manchester
Tonatiuh Pena Centeno
Head of bioinformatics core unit
German Center for Neurodegenerative Diseases
Kerry Ressler
Emory University
Michael Gaebler
Group leader
Max Planck Institute for Human Cognitive and Brain Sciences
EWA BALKOWIEC-ISKRA
Professor
Medical University of Warsaw
Thomas G Schulze
Clinical Professor
SUNY Upstate Medical University
Keith Smith
University Of Strathclyde
Lalit Kaurani
Group Leader
Institute of Physiology of the Czech Academy of Sciences
Urs Heilbronner
Research Associate (tenured)
University Hospital, LMU Munich
Til Ole Bergmann
Associate Professor
Johannes Gutenberg Universität Mainz
Madhur Mangalam
Assistant Professor
University of Nebraska - Lincoln
Udo Dannlowski
University of Münster
Nicola Warren
University of Queensland
Isabel Maurus
University Hospital
Tilo Kircher
Professor, Chair
University of Marburg
Frank Padberg
Professor of Psychiatry and Psychotherapy
Ludwig-Maximilians-Universität München
Martien Kas
Scientific Staff, Professor
Rijksuniversiteit Groningen
Sophia Stoecklein
LMU University Hospital
Dan Siskind
Professor
University of Queensland
James Cole
Associate Professor in Neuroimage Analysis
University College London
Eva Reininghaus
Univ. Prof. PD, MD, MBA
Medical University of Graz
Michaela V. Bonfert
Ludwig-Maximilians-Universität München
Peter Falkai
Chair
Ludwig-Maximilians-Universität München
Make your next move.
Prepare your application
Review drafts before you send them.